source
- GSK and Ionis report functional cure in 20% of hepatitis B patients with bepirovirsen in early trialsGSK and Ionis disclosed results from two clinical studies of their RNA‑based injection, bepirovirsen, aimed at achieving a functional cure for chronic hepatitis B. In both trials about one‑fifth o…
- GSK reports strong Phase 3 results for Ionis-licensed chronic hepatitis B therapyGSK disclosed data from two late‑stage trials of a chronic hepatitis B treatment it licensed from Ionis Pharmaceuticals. The studies evaluated the drug’s efficacy and safety in patients with chroni…